ArticleFuture oncology (London, England)2022
Plain language summary of the HERO study comparing relugolix with leuprolide for men with advanced prostate cancer.
Neal D Shore et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it